Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

FDA grants Fast Track designation for Repligen's RG3039 to treat Spinal Muscular Atrophy

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

New research on spinal muscular atrophy

New research on spinal muscular atrophy

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Evotec, PsychoGenics partner to offer integrated CNS drug discovery solutions

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Caliper first quarter revenue increases 25% to $35.8 million

Caliper first quarter revenue increases 25% to $35.8 million

FightSMA to host panel discussions on spinal muscular atrophy

FightSMA to host panel discussions on spinal muscular atrophy

Repligen anticipates 30% increase in total revenues for 2011

Repligen anticipates 30% increase in total revenues for 2011

Quest Diagnostics completes Athena Diagnostics acquisition

Quest Diagnostics completes Athena Diagnostics acquisition

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Life Sciences introduces ELISA system to detect SMN protein

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Top-line results from Repligen RG2417 Phase 2b trial results in patients with bipolar depression

Scientists discover new way to generate human motor nerve cells

Scientists discover new way to generate human motor nerve cells

San Diego Hospice is California's first provider of unique children care program

San Diego Hospice is California's first provider of unique children care program

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen third quarter total revenue increases 26% to $7,068,000

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA awards Repligen $1.4M for research of new compound with therapeutic potential for SMA

MDA commits to invest funds in FSMA Quinazoline Program

MDA commits to invest funds in FSMA Quinazoline Program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program

MDA supports Repligen with $1.4M grant for RG3039 Spinal Muscular Atrophy development program